Rationale
=========

In patients with symptomatic asthma receiving ICS or ICS+LABA, Phase III studies have demonstrated improved lung function with tiotropium Respimat^®^, a once-daily long-acting anticholinergic bronchodilator. The efficacy of some treatments (eg ICS and omalizumab), appears higher in T~H~2-high phenotypes, but no specific treatments are available that work equally well in both T~H~2-high and T~H~2-low phenotypes. We explored whether T~H~2 biomarker status influenced responses to tiotropium in patients with moderate symptomatic asthma.

Methods
=======

In two replicate Phase III, randomized, double-blind, placebo-controlled, parallel-group trials (NCT01172808/NCT01172821), patients with moderate symptomatic asthma, using medium-dose ICS (400-800 µg budesonide equivalent), were administered once-daily tiotropium Respimat^®^ 5 µg or 2.5 µg, placebo, or salmeterol (active comparator without inferential analysis). Co-primary endpoints included peak and trough FEV~1~ response (difference from baseline) at 24 weeks. Pre-planned analyses (pooled population) were performed in T~H~2-high and T~H~2-low subgroups defined at baseline as total serum IgE ≤ or \>430 µg/L) or blood eosinophils ≤ or \>0.6×10^9^/L.

Results
=======

Of 1545 patients in the full analysis set who received tiotropium or placebo, 915/1455 were reported with IgE \>430 µg/L and 300/1461 with an eosinophil count of \>0.6×10^9^/L. Peak FEV~1~ improved with tiotropium versus placebo, independent of IgE (p\<0.0001 both doses) and eosinophil count (p\<0.0001 both doses). Trough FEV~1~ also improved with tiotropium versus placebo, irrespective of IgE (p\<0.0001 both doses) and eosinophil count (p\<0.005 both doses).

Conclusions
===========

Once-daily tiotropium Respimat^®^ as add-on to ICS reduces airflow obstruction in patients with moderate symptomatic asthma, independent of T~H~2 phenotype, and thus may potentially provide an important therapeutic option.
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